Crinone Gel: Uses in IVF, Side Effects, and Dosing

Crinone is a vaginal gel that delivers progesterone directly to the reproductive tract, used primarily as luteal phase support during fertility treatments and as part of hormone replacement therapy. It comes in two strengths, 4% (45 mg) and 8% (90 mg), and its distinguishing feature is a bioadhesive polymer base that sticks to the vaginal lining and releases progesterone slowly over time. The gel has become one of the most widely used alternatives to painful intramuscular progesterone injections in assisted reproduction, though some of the assumptions about exactly how it works have been challenged by newer research.

How the Gel Delivers Progesterone

Crinone’s formulation is built around polycarbophil, a bioadhesive polymer. When the gel contacts the vaginal lining, carboxylic acid groups on the polymer form hydrogen bonds with the mucosal surface, which keeps the gel in place rather than letting it drain away. This extended contact time means progesterone is released gradually into the surrounding tissue, absorbed through the mucosal capillaries, and enters the bloodstream while bypassing the liver’s first-pass metabolism. Avoiding that liver metabolism is relevant because oral progesterone loses a significant fraction of its dose to liver processing before it ever reaches the uterus.¹

Characterization studies have shown that progesterone sits within the gel matrix in crystalline form, and the globule size distribution across different manufacturing batches is highly consistent, which matters for getting a predictable release rate from one applicator to the next.²

An early study in postmenopausal women demonstrated that even the lower 45 mg dose, given every other day, was enough to transform an estrogen-primed endometrium from a proliferative to a secretory state. Glands became more coiled and ramified, mitotic activity dropped, and progesterone receptor content decreased in a pattern consistent with genuine progestational change.³ That finding was important at the time because it suggested the sustained-release approach could protect the uterine lining from unopposed estrogen even at fairly modest progesterone doses.

The “First Uterine Pass” Debate

For years, one popular explanation for why vaginal progesterone works so well despite producing lower blood levels than injections was the so-called “first uterine pass effect,” the idea that progesterone travels directly from the vagina to the uterus through some kind of local vascular shortcut. This concept became almost dogmatic in reproductive medicine circles, but the evidence behind it is weaker than many clinicians assume.

The most cited study supporting the theory compared endometrial tissue levels in postmenopausal women receiving either vaginal gel or intramuscular progesterone. The endometrial tissue levels were not actually significantly different between the two groups. What was different was the ratio of serum-to-endometrial progesterone, and that ratio looked more impressive for the vaginal route mainly because vaginal progesterone produces much lower serum levels in the first place. There is no portal vascular system connecting the vagina directly to the uterus the way the portal vein connects the gut to the liver. Any progesterone absorbed vaginally still has to travel through veins, the heart, and arteries before it reaches the endometrium.⁴

This does not mean vaginal progesterone is ineffective. Clinical outcomes across many trials show it works well. But the mechanism is probably more straightforward than the “first pass” theory suggests: the bioadhesive gel keeps progesterone in prolonged contact with the vaginal mucosa, which produces sustained local absorption and a steady supply to the uterus via normal circulation.

How It Compares to Intramuscular Progesterone in IVF

The core question for most people encountering Crinone is whether it works as well as intramuscular progesterone in oil (IMP), the older standard for luteal phase support after IVF. The short answer is that pregnancy, implantation, and live birth rates are comparable across the two routes in most patients, and the gel is dramatically better tolerated.

A prospective randomized study found that pregnancy rates, ongoing or delivered pregnancy rates, and failed pregnancy rates were all similar between Crinone and IMP. But patient satisfaction scores told a different story: on a 1-to-5 scale, Crinone scored 4.4 compared to 2.8 for injections.⁵ Anyone who has given themselves daily oil-based intramuscular injections in the buttock for weeks on end will understand why that gap exists. The injections are painful, can cause abscesses, and leave lasting soreness at the injection site.

A large prospective trial went further and suggested Crinone might actually outperform injections in younger patients. Women under 35 who received vaginal progesterone had significantly higher delivery rates than those on intramuscular progesterone. In older patients, the two were equally effective.⁶ This is one of the few studies to show a potential advantage for the gel rather than simple equivalence, and it has not been universally replicated, so it is worth noting but not overstating.

Results from frozen embryo transfer cycles tell a similar story of equivalence. A randomized trial in frozen-thawed embryo transfers found no meaningful differences in live birth rates, clinical pregnancy rates, implantation rates, or miscarriage rates between the gel and injection groups.⁷ A separate study specifically using vitrified blastocyst transfers reached the same conclusion, with implantation, clinical pregnancy, and live birth rates nearly identical between routes.⁸ A retrospective cohort looking at blastocyst cryopreserved single embryo transfers also found similar rates of live birth, biochemical pregnancy, spontaneous miscarriage, and clinical pregnancy.

One nuance worth knowing: an earlier trial noted that while clinical and ongoing pregnancy rates were similar, the Crinone group had somewhat higher rates of biochemical pregnancy loss and lower serum progesterone levels. The authors concluded Crinone was an acceptable alternative but flagged the bleeding pattern differences as something requiring further study.⁹ Biochemical losses are early pregnancies detected by a blood test that don’t progress to a clinical pregnancy visible on ultrasound. Whether this difference is clinically meaningful or a statistical artifact of lower circulating progesterone levels remains unclear.

Crinone Versus Other Vaginal Progesterone Products

Crinone is not the only vaginal progesterone on the market. Micronized progesterone capsules (sold under names like Utrogestan or Prometrium) are also commonly used vaginally, even though many of them were originally designed for oral use. How do the two compare?

A head-to-head trial found no statistically significant differences in ongoing pregnancy rates, implantation rates, or miscarriage rates between Utrogestan capsules and Crinone gel. Tolerability was good in both groups, with few drug-related side effects in either arm.¹⁰ However, a separate study using blastocyst-stage transfers found that the Crinone group had significantly higher clinical pregnancy and implantation rates than the Utrogestan group.¹¹

The inconsistency between these studies is fairly typical of fertility research, where patient populations, embryo quality, transfer stage, and clinic-level factors all introduce variability. The practical takeaway is that both formulations are considered effective, and the choice often comes down to what is available, what the clinic prefers, and what the patient tolerates best. Capsules can be messier (they tend to leak more), while the gel can leave a waxy residue that some women find annoying.

Side Effects and the Residue Problem

Crinone’s side effects are generally mild. Perineal irritation is the most commonly noted local issue, reported by roughly a fifth of patients in one comparative study.¹² Systemic side effects appear to be minimal. In a study of women with secondary amenorrhea receiving Crinone as part of hormone therapy, the incidence of most side effects, including mood-related symptoms, actually decreased compared to the estrogen-only phase of treatment, and no patient experienced a serious drug-related adverse event.

The complaint you will hear most often from women using Crinone is not really a medical side effect at all: it is the gel residue. The same bioadhesive property that makes Crinone effective also means the gel base does not dissolve cleanly. Over days of use, a chalky or waxy buildup can accumulate in the vagina. Many clinics recommend gentle removal of residue with a finger or during bathing, though there is no standardized guidance. This buildup is cosmetically unpleasant but not harmful, and it does not seem to interfere with progesterone absorption.

Sexual Intercourse and Progesterone Absorption

One piece of practical information that rarely makes it into patient leaflets: sexual intercourse can significantly reduce how much progesterone your body absorbs from the gel. A randomized controlled trial found that when couples had intercourse after vaginal progesterone gel was applied, the woman’s serum progesterone levels dropped markedly compared to abstinence. The study also detected significantly elevated progesterone levels in male partners whose female partners had used the gel, confirming that the progesterone was being physically transferred during intercourse.¹³

This is the kind of finding that matters practically. If you are using Crinone for luteal phase support during an IVF cycle, timing intercourse to avoid the window right after application makes sense. Most clinics advise a gap of several hours between gel application and intercourse, though specific recommendations vary. The transferred progesterone does not appear to pose a health risk to male partners, but the reduction in the woman’s progesterone levels is the real concern.

Preventing Preterm Birth in Women With Short Cervix

Outside the fertility clinic, Crinone and other vaginal progesterone gels have an important role in preventing preterm birth. In women found to have a short cervix on mid-pregnancy ultrasound, vaginal progesterone substantially reduces the chance of delivering too early.

A large multicenter, double-blind, placebo-controlled trial studied women with a cervical length of 10 to 20 mm at midtrimester. Those receiving daily vaginal progesterone gel had roughly half the rate of preterm birth before 33 weeks compared to placebo. The benefit extended to very early preterm birth before 28 weeks, and the treatment group also had lower rates of respiratory distress syndrome, low birth weight, and combined neonatal illness or death.¹⁴ These results were consistent with earlier evidence from the Fetal Medicine Foundation, and together they established vaginal progesterone as a standard intervention for women identified with short cervix.¹⁵

It is worth noting that this application specifically applies to women with a sonographically measured short cervix. Vaginal progesterone has not been shown to prevent preterm birth in the general population of pregnant women or in those with other risk factors like a history of preterm birth but a normal cervical length. The screening and treatment need to go together.

Use in Hormone Replacement Therapy and Amenorrhea

Crinone was originally developed not just for fertility treatment but also for hormone replacement therapy. In women receiving estrogen, adding a progestogen is necessary to protect the endometrium from the overgrowth that unopposed estrogen can cause. Vaginal progesterone gel offers a way to deliver that progestational protection with fewer systemic effects than oral progestins.

In women with secondary amenorrhea receiving estrogen therapy, cyclic Crinone induced withdrawal bleeding in about four out of five patients at both the 4% and 8% doses, confirming adequate endometrial effect.¹⁶ Biopsies showed progestational changes in the vast majority of patients at both doses, with the 8% strength achieving secretory transformation in essentially all evaluable endometrial samples. The relatively low systemic exposure is potentially advantageous for women concerned about progesterone-related mood symptoms or other systemic side effects seen with oral formulations.

Dosing and When to Stop

The standard IVF protocol uses the 8% gel (90 mg per application) once daily, typically starting the day after egg retrieval or on the day of embryo transfer, depending on clinic protocol. Some clinics have used twice-daily dosing. One study analyzing 144 IVF/ICSI cycles used 90 mg twice daily and found higher pregnancy rates compared to daily intramuscular progesterone, though this was not a large randomized trial and the optimal frequency remains debated.¹⁷ For frozen embryo transfer cycles specifically, the best timing and dose of Crinone have not been definitively established, and protocols vary significantly between clinics.¹⁸

The question of when to stop progesterone support after a positive pregnancy test is one that causes significant anxiety. In a natural pregnancy, the corpus luteum produces progesterone for the first several weeks until the placenta takes over, a transition typically complete by about 8 to 10 weeks of gestation. In IVF cycles, the corpus luteum may be absent or dysfunctional because of the way ovarian stimulation and egg retrieval work, so supplementation is needed to bridge that gap. Most clinics continue Crinone until somewhere between 8 and 12 weeks of pregnancy, though exact stopping points vary. Tapering versus abrupt discontinuation is another area without strong consensus. The anxiety around stopping is understandable given how much is invested in an IVF cycle, but the placenta is the long-term progesterone factory, and continuing supplementation indefinitely provides no proven benefit once that transition is complete.

Monitoring Progesterone Levels on Crinone

A common source of confusion for patients using Crinone is seeing low serum progesterone levels on blood work and panicking. Vaginal progesterone consistently produces lower circulating blood levels than intramuscular injections, sometimes dramatically so. This does not mean the drug is not working. The progesterone is being delivered locally to the reproductive tract, and serum levels are a poor proxy for what is actually reaching the endometrium.

Many clinics have moved away from routine progesterone level monitoring in patients using vaginal formulations precisely because the numbers cause unnecessary alarm without providing useful clinical information. If your doctor is measuring serum progesterone while you are on Crinone, the thresholds they use should be different from what they would expect with intramuscular progesterone. A level that would look inadequate on injections may be perfectly normal on vaginal gel. This is one of those cases where knowing the context behind a lab number matters more than the number itself.